ArticleCellular and molecular life sciences : CMLS2026
HUVEC-derived exosomes alleviate lipopolysaccharide-induced acute lung injury inflammation by restoring the balance of mitochondrial fusion and division.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is a life-threatening condition with high morbidity and mortality, where acute lung injury (ALI) is one of the earliest and most severe complications. Macrophage-mediated overactivation of inflammation and subsequent release of pro-inflammatory cytokines cause significant damage to pulmonary epithelial cells, playing a critical role in the progression of sepsis-induced ALI. This study successfully investigated the role of HUVEC-derived exosomes in the treatment of ALI and designed a novel engineered vesicle for therapeutic application.
resultsWe successfully isolated and characterized HUVEC-derived exosomes. These exosomes were found to reduce inflammatory cytokine release from macrophages and restore the viability of lung epithelial cells. Furthermore, extracellular vesicles derived from HUVECs effectively suppress proinflammatory cytokine release from M1-polarized macrophages. Significantly, HUVEC-derived exosomes improved the balance between mitochondrial fusion and fission, reducing the release of mitochondrial DNA (mtDNA) and nuclear translocation of NF-κB. miRNA profiling and subsequent inhibition experiments identified miR-520d-3p as a key factor delivered by HUVEC exosomes. This miRNA was shown to decrease the expression of MARCH5, inhibiting ubiquitination of the mitochondrial fusion protein Mfn1, thus promoting mitochondrial fusion and reducing mtDNA release. In addition, we designed and synthesized a novel engineered vesicle, exosome@IPR, by encapsulating ipratropium bromide within HUVEC-derived exosomes to target mitochondrial fusion. This engineered vesicle significantly reduced lung injury and improved the survival rate in mice.
conclusionOur findings uncover a novel therapeutic mechanism by which miR-520d-3p delivered via HUVEC-derived exosomes alleviates inflammation in sepsis-induced ALI. This occurs through modulation of mitochondrial dynamics, specifically by restoring the balance between mitochondrial fusion and fission, thereby mitigating macrophage-induced lung injury in sepsis. Our findings revealed that extracellular vesicles derived from HUVECs act as a natural therapeutic agent by restoring the balance between mitochondrial fusion and fission. Building on this, we designed and synthesized an engineered vesicle named exosome@IPR that more effectively reverses the LPS-induced imbalance in mitochondrial dynamics, reduces inflammation, and improves survival in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.